| 300723 | 一品红 | -1.57 | 1.53 | -3283.59 | | --- | --- | --- | --- | --- | | 600812 | 华北制药 | -1.79 | 1.56 | -3211.05 | | 603707 | 健友股份 | -1.57 | 1.13 | -3199.60 | | 000513 | 丽珠集团 | -1.18 | 1.89 | -2646.84 | | 688266 | 泽璟制药 | -1.79 | 1.22 | -2023.83 | | 688687 | 凯因科技 | -1.23 | 5.23 | -1814.98 | | 688238 | 和元生物 | -2.26 | 2.31 | -1499.70 | | 002007 | 华兰生物 | -0.66 | 0.83 | -1452.56 | | 600645 | 中源协和 | -2.15 | 2.61 | -1354.50 | | 600223 | 福瑞达 | -0.35 | 1.25 | -1245.76 | | 688136 | 科兴制药 | -2.66 | 3.70 | -788.30 | ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

创新药概念股集体走低，奥翔药业（603229）触及跌停，科兴制药跌超10%，塞力医疗（603716）、德 展健康（000813）、海创药业跌幅居前。 ...

Market Overview - On August 1, the Xinjiang state-owned enterprise reform sector rose by 2.15%, led by Tianfu Energy [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Stock Performance - Tianfu Energy (600509) closed at 6.59 with a gain of 2.01%, trading volume of 344,200 shares and a turnover of 227 million yuan [1] - Other notable stocks included Tiankang Biological (002100) with a 0.63% increase, and ST Zhongji (000972) with a 0.31% increase [1] - The overall performance of the Xinjiang state-owned enterprise reform sector showed mixed results, with some stocks experiencing slight declines [1] Capital Flow - The Xinjiang state-owned enterprise reform sector saw a net outflow of 441 million yuan from institutional investors, while retail investors contributed a net inflow of 214 million yuan [2] - The sector's capital flow indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors remained active [2] Individual Stock Capital Flow - Qing Song Jian Hua (600425) had a net inflow of 14.21 million yuan from institutional investors, while Tianfu Energy (600509) saw a net inflow of 9.14 million yuan [3] - Conversely, stocks like Yili Te (600197) and Tiankang Biological (002100) experienced net outflows from institutional investors, indicating varying levels of confidence among different stocks [3]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, highlighting the lack of available vaccines in China [1][2] Group 1: Market Performance - Shenyuan Biological (申联生物) rose by over 10%, with a year-to-date increase of 42.60% and a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market cap of 3.252 billion and a year-to-date rise of 34.04% [2] - Guanhao Biological (冠昊生物) saw a 7.70% increase, with a market cap of 4.969 billion and a year-to-date increase of 55.65% [2] - Sealy Medical (塞力医疗) rose by 5.60%, with a market cap of 6.055 billion and an impressive year-to-date increase of 339.06% [2] - Other notable performers include Kanglao Weishi (康乐卫士) up 4.98%, Jinhai Biological (金河生物) up 4.62%, and Weilan Biological (蔚蓝生物) up 4.41% [1][2] Group 2: Regulatory and Health Measures - The 2025 Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding sites and using repellents [1] - Travelers to Chikungunya endemic areas are advised to enhance their preventive awareness to avoid infection [1] - Currently, there is no available vaccine for the Chikungunya virus in China, indicating a potential market opportunity for vaccine development [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, which has heightened awareness and demand for related medical solutions [1][2]. Group 1: Stock Performance - Shenyuan Biological (申联生物) rose by 10.33%, with a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market capitalization of 3.252 billion [2] - Guanhao Biological (冠昊生物) saw a rise of 7.70%, with a market capitalization of 4.969 billion [2] - Seer Medical (塞力医疗) grew by 5.60%, with a market capitalization of 6.055 billion [2] - Kanglao Guardian (康乐卫士) increased by 4.98%, with a market capitalization of 4.793 billion [2] - Jinhai Biological (金河生物) rose by 4.62%, with a market capitalization of 5.594 billion [2] - Weilan Biological (蔚蓝生物) increased by 4.41%, with a market capitalization of 3.831 billion [2] - Yongshun Biological (永顺生物) rose by 3.94%, with a market capitalization of 2.742 billion [2] - Dezhan Health (德展健康) increased by 3.51%, with a market capitalization of 10.5 billion [2] - Junzheng Group (君正集团) rose by 3.37%, with a market capitalization of 46.6 billion [2] - Kanghua Biological (康华生物) increased by 3.19%, with a market capitalization of 10.4 billion [2] Group 2: Market Context - The 2025 version of the Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding grounds and using repellents [1] - There is currently no available vaccine for the Chikungunya virus in China, which may drive demand for vaccine development [1] - Free nucleic acid screening for Chikungunya virus is being conducted in Lecong Town, Shunde District, targeting close contacts of confirmed cases [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000813 证券简称：德展健康 公告编号：2025-060 德展大健康股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 德展大健康股份有限公司（以下简称"公司"、"本公司"）（证券简称：德展健康，证券代码：000813） 股票连续2个交易日（2025年7月30日、7月31日）内日收盘价格涨幅偏离值累计达到23.06%，根据《深 圳证券交易所交易规则》等有关规定，属于股票交易异常波动的情形。 二、公司关注及核实情况说明 针对公司股票交易异常波动，公司董事会对有关事项进行了核查，并就相关事项向公司控股股东及其一 致行动人进行了函询，现将有关情况说明如下： （一）截至本公告披露日，本公司前期披露的信息不存在需要更正、补充之处； （二）截至本公告披露日，公司未发现近期公共传媒报道或市场传闻对本公司股票交易价格产生较大影 响的未公开重大信息； 五、备查文件 （一）公司控股股东及其一致行动人出具的《关于德展大健康股份有限公司股票交易异常波动问询函 ...

Core Viewpoint - The company has completed the cancellation of repurchased shares, which amounts to 67,850,450 shares, representing 3.13% of the total share capital before cancellation [2][5]. Group 1: Share Repurchase Implementation - The company approved a share repurchase plan at the 2024 first extraordinary general meeting, allowing for the repurchase of shares using between RMB 200 million and RMB 300 million within 12 months [3]. - The repurchase price was set at a maximum of RMB 3.59 per share, with the funds sourced from the company's own funds and loans from financial institutions [3]. - The actual repurchase period was from September 3, 2024, to July 15, 2025, with a total of 67,850,450 shares repurchased at an average price of RMB 2.96 per share, totaling RMB 200,884,766.50 [4]. Group 2: Share Cancellation Details - The cancellation of the repurchased shares was confirmed by the China Securities Depository and Clearing Corporation on July 30, 2025, with the total share capital reduced from 2,164,955,990 shares to 2,097,105,540 shares [2][5]. - The shares were canceled from both self-funded and loan accounts, with 28,567,500 shares from self-funding and 39,282,950 shares from loans [2][5]. Group 3: Impact on Shareholder Equity - The cancellation of shares is expected to enhance earnings per share and improve shareholder returns without adversely affecting the company's financial, operational, or debt obligations [6]. - The cancellation will not change the company's control or affect its listing status [6]. Group 4: Future Arrangements - The company will amend relevant provisions in its articles of association and complete necessary business registration and filing procedures as per legal requirements [6].

德展健康7月31日发布公告，股票连续2个交易日（2025年7月30日、7月31日）内日收盘价格涨幅偏离值 累计达到23.06%，根据《深圳证券交易所交易规则》等有关规定，属于股票交易异常波动情形。 经核 实，近期公司生产经营情况正常，截至本公告披露日，内外部经营环境未发生重大变化。经函询公司控 股股东新疆凯迪投资有限责任公司及其一致行动人，公司控股股东及其一致行动人、公司实际控制人均 不存在有关本公司的应披露而未披露的重大事项，也不存在其他与公司有关的正处于筹划阶段的重大事 项，同时亦未在公司股票交易异常波动期间买卖本公司股票。 ...